A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery.

Opfermann, P; Derhaschnig, U; Felli, A; Wenisch, J; Santer, D; Zuckermann, A; Dworschak, M; Jilma, B; Steinlechner, B

Opfermann, P; Derhaschnig, U; Felli, A; Wenisch, J; Santer, D; Zuckermann, A; Dworschak, M; Jilma, B; Steinlechner, B.

Affiliation

Opfermann P; Division of Cardiothoracic and Vascular Anesthesia and Intensive Care, Medical University of Vienna, Vienna, Austria.

Clin Exp Immunol ; 180(1): 131-42, 2015 Apr.

Article in En | MEDLINE | ID: mdl-25402332

Subject(s)

Coronary Artery Bypass/methods; Myocardial Reperfusion Injury/prevention & control; Postoperative Complications/prevention & control; Receptors, Interleukin-8A/antagonists & inhibitors; Receptors, Interleukin-8B/antagonists & inhibitors; Sulfonamides/administration & dosage; Aged; Female; Humans; Leukocyte Count; Male; Middle Aged; Myocardial Reperfusion Injury/blood; Neutrophils/metabolism; Pilot Projects; Postoperative Complications/blood; Time Factors

Key words

CXCL8; CXCR1/2; Phase II study; cardiopulmonary bypass; postoperative inflammation

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Postoperative Complications / Sulfonamides / Myocardial Reperfusion Injury / Coronary Artery Bypass / Receptors, Interleukin-8A / Receptors, Interleukin-8B Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Exp Immunol Year: 2015 Document type: Article Affiliation country: Austria Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google